Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

One of the leading triggers for multiple sclerosis (MS) is an infection with the Epstein-Barr virus. However, certain gene variants also play an important role.